769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1827763414210969600 |
|---|---|
| author | Matthijs D Linssen Divya Lenkala Brian McCarthy Cynthia Nijenhuis Kristen Balogh Mark DeMario Emily Jackson Jessica SW Borgers Victoria Kohler Sebastian Hymson Katya Esaulova Joong Hyuk F Sheen Olivia Finney Sebastian Klobuch Richard B Gaynor John B Haanen Marit MVan Buuren |
| author_facet | Matthijs D Linssen Divya Lenkala Brian McCarthy Cynthia Nijenhuis Kristen Balogh Mark DeMario Emily Jackson Jessica SW Borgers Victoria Kohler Sebastian Hymson Katya Esaulova Joong Hyuk F Sheen Olivia Finney Sebastian Klobuch Richard B Gaynor John B Haanen Marit MVan Buuren |
| author_sort | Matthijs D Linssen |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:51:57Z |
| format | Article |
| id | doaj.art-4c490eaec4ad411cb6ce86a8a0873ef5 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:51:57Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-4c490eaec4ad411cb6ce86a8a0873ef52023-11-13T14:40:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0769769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanomaMatthijs D Linssen0Divya Lenkala1Brian McCarthy2Cynthia Nijenhuis3Kristen Balogh4Mark DeMario5Emily Jackson6Jessica SW Borgers7Victoria Kohler8Sebastian Hymson9Katya Esaulova10Joong Hyuk F Sheen11Olivia Finney12Sebastian Klobuch13Richard B Gaynor14John B Haanen15Marit MVan Buuren163 Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands1BioNTech US Inc., Cambridge, MA, USA1BioNTech US Inc., Cambridge, MA, USA2Netherlands Cancer Institute, Cambridge, MA, USA5BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA1Netherlands Cancer Institute, Amsterdam, Netherlands2BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA2BioNTech US, Cambridge, MA, USA1Netherlands Cancer Institute, Amsterdam, Netherlands2BioNTech US, Cambridge, MA, USA1Netherlands Cancer Institute, Amsterdam, Netherlands2BioNTech US, Cambridge, MA, USA |
| spellingShingle | Matthijs D Linssen Divya Lenkala Brian McCarthy Cynthia Nijenhuis Kristen Balogh Mark DeMario Emily Jackson Jessica SW Borgers Victoria Kohler Sebastian Hymson Katya Esaulova Joong Hyuk F Sheen Olivia Finney Sebastian Klobuch Richard B Gaynor John B Haanen Marit MVan Buuren 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma Journal for ImmunoTherapy of Cancer |
| title | 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma |
| title_full | 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma |
| title_fullStr | 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma |
| title_full_unstemmed | 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma |
| title_short | 769 Interim clinical and translational data from NTC-001, a phase I study to evaluate the non-engineered neoantigen-specific T cell product BNT221 in patients with advanced or metastatic melanoma |
| title_sort | 769 interim clinical and translational data from ntc 001 a phase i study to evaluate the non engineered neoantigen specific t cell product bnt221 in patients with advanced or metastatic melanoma |
| work_keys_str_mv | AT matthijsdlinssen 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT divyalenkala 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT brianmccarthy 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT cynthianijenhuis 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT kristenbalogh 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT markdemario 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT emilyjackson 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT jessicaswborgers 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT victoriakohler 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT sebastianhymson 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT katyaesaulova 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT joonghyukfsheen 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT oliviafinney 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT sebastianklobuch 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT richardbgaynor 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT johnbhaanen 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma AT maritmvanbuuren 769interimclinicalandtranslationaldatafromntc001aphaseistudytoevaluatethenonengineeredneoantigenspecifictcellproductbnt221inpatientswithadvancedormetastaticmelanoma |